Understanding the Risk Factors for Anaemia in Adults with HIV
Research shows a large proportion of adults living with HIV have been found to have anaemia, with several risk factors contributing to its prevalence
Related Articles
Daratumumab Significantly Improves PFS, Extends OS in Smoldering Myeloma
Subcutaneous daratumumab reduced the risk for disease progression or death vs active monitoring in intermediate- or high-risk smoldering multiple myeloma.
Behind the Scenes: Patient Education and Decision-Making for CAR T
Panelists discuss how health care providers engage in vital conversations with patients about CAR T therapy, focusing on comprehensive education, emotional support, and clear communication…
Stay Updated: December 2024 News from AHNS – Corrected Meeting Dates!
Email from American Head and Neck Society This year, many of our AHNS Sections and Services have been working tirelessly to deliver top-notch educational…
The OncFive: Top Oncology Articles for the Week of 12/15
The FDA awards accelerated approval to encorafenib regimen in BRAF V600E+ CRC, ensartinib wins approval in ALK+ non–small cell lung cancer, and more.
Endometrial Cancer Classification and Management in the Molecular Subtyping Era
A 65-year-old woman presented with a 6-month history of postmenopausal vaginal bleeding, and endometrial biopsy showed grade 2 endometrioid adenocarcinoma. What would you do next?
New Developments in CAR T Treatments Webinar Infographic Series
The following infographics are based on New Developments in CAR T Treatments Webinar Series, which aired on Tuesday, September 10, at 12 p.m. CDT and featured…
Oncological Safety of MRI-Informed Biopsy Decision-Making in Men With Suspected Prostate Cancer
This cohort study assesses the feasibility and safety of a community-based magnetic resonance imaging (MRI) diagnostic strategy in men with suspected prostate cancer using 3-year…
What’s new in breast cancer research? SABCS24 looks at ctDNA, AI and ‘right-sizing’ treatment
More than 11,000 researchers, clinicians, patient advocates and drugmakers gathered last week at the San Antonio Breast Cancer Symposium to share the latest treatments, tricks…
Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC
The neoadjuvant/adjuvant pembrolizumab and chemotherapy combination was approved by the FDA in October 2023 for use in this patient population.